figshare
Browse

Kaplan-Meier analysis Of (A) progression-free survival and (B) overall survival by EGFR TKI therapy prior to osimertinib used in second line.

Download (99.33 kB)
journal contribution
posted on 2024-05-16, 17:46 authored by Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, Sheng-Yen Hsiao, Chin-Chou Wang, Chih-Feng Chian, Te-Chun Hsia, Yuh-Min Chen
<p>Kaplan-Meier analysis Of (A) progression-free survival and (B) overall survival by EGFR TKI therapy prior to osimertinib used in second line.</p>

History

Related Materials

  1. 1.
    DOI - Is supplement to Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer

Usage metrics

    PLOS ONE

    Categories

    Keywords

    significantly impact outcomeseffectiveness remain scarcedisease control ratecentral nervous system67 %), 5389 &# 821185 &# 821159 &# 821149 &# 821130 &# 821121 &# 8211positive locally advancedmonth pfs rate2l ), 3l8 &# 8211xlink "> osimertinibobjective response ratemonth os rate95 &# 821118 &# 821169 ), 13median pfs valuesci ]: 8without cns metastasismedian overall survival79 ), 10&# 88053 ),median pfspositive nonfree survivalmedian timemedian progression2l therapyworld datatreatment discontinuationtaiwan supportsubgroup analysesreceived osimertinibprior linesprior afatinibosimertinib monotherapymetastatic nonmean agegefitinib treatmentdemonstrated efficacyconfidence intervalclinical trialsclinical benefits95 );63 years46 %,41 );38 %.

    Licence

    CC BY 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC